Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder

Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22550279

DOI
10.1345/aph.1Q326

Original Paper URL
http://www.theannals.com/content/46/5/642.abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Antidepressive Agents /adverse effects /economics /therapeutic use; Antipsychotic Agents /administration & dosage /adverse effects /economics /therapeutic use; Aripiprazole; Benzodiazepines /adverse effects /economics /therapeutic use; Cost-Benefit Analysis /economics /statistics & numerical data; Decision Support Techniques; Depressive Disorder, Major /diagnosis /drug therapy /economics; Dibenzothiazepines /adverse effects /economics /therapeutic use; Drug Combinations; Drug Costs /statistics & numerical data; Drug Resistance; Fluoxetine /adverse effects /economics /therapeutic use; Health Care Costs /statistics & numerical data; Humans; Piperazines /adverse effects /economics /therapeutic use; Quetiapine Fumarate; Quinolones /adverse effects /economics /therapeutic use

AccessionNumber
22012020573

Date bibliographic record published
06/07/2012